Be Biopharma

Venture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi

Biopharma financings during the second quarter of 2022 reached $12.5bn. The largest was by Blueprint Medicines Corporation (precision therapies for cancer and blood disorders) through an arrangement

Stock market investors may be holding back dollars from public biopharmaceutical firms as macroeconomic issues and other factors severely impact company valuations, but venture capital investment has

National Resilience, Inc. has closed a $625m series D venture capital round, bringing its total VC funding during the past 10 months to more than $1.2bn, including a previously unannounced $600m seri